United States · 
What does Bioventures Investors invest in?
Bioventures Investors invests most often at Series B and Series C (52% of the rounds on record), in sectors such as Health, Medical Device and Diagnostics.
Bioventures Investors highlights
- 01
21 rounds on record
- 02
Mostly Series B and Series C: 52% of its rounds
- 03
Sole investor in 3 rounds, median $3.4M
- 04
6 exits from the portfolio
What they do
WE INVEST IN EMERGING & GROWTH STAGE MEDTECH COMPANIESFrom their own website
- Type
- Private equity (from a list, unverified)
- Cheque size
- $5.0M – $25M as they say
- Stages
- SeedSeries ASeries BGrowth
- Sectors
- HealthMedical DeviceDiagnostics
- Based in
- Wellesley, United States
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first21 appearances
- 2019
2 rounds
- Nov
- Oct
- 2016
1 round
- Jul
- 2010
1 round
- Sept
- 2009
1 round
- Mar
- 2008
2 rounds
- Oct
- Mar
- 2007
7 rounds
- Dec
- Sept
- Jun
- Jun
- Apr
- Jan
- Jan
- 2006
1 round
- Apr
- 2005
1 round
- May
- 2004
2 rounds
- Jan
- Jan
- 2003
1 round
- Sept
- 2002
1 round
- Dec
- 2000
1 round
- Aug
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration6 named
JLJames LousararianManaging Director of Bioventures Investors IV Management LLCiForm ADV
JTJeffrey Thomas BarnesManaging Director of Bioventures Investors IV Management LLCiForm ADV
JPJonathan Paull GertlerManaging Director of Bioventures Medtech Growth Capital Management LLCiForm ADV
MEMarc Evan GoldbergManaging Director of the General PartneriFiling they signed
PLPeter Lawrence FeinsteinManaging Director of Bioventures Investors II, LLCiForm ADV
WGWalter GilbertManaging Director of Bioventures Investors II, LLCiForm ADV
We also hold 11 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$303Mgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- Bioventures II Management Corporation
- SEC number
- CRD 161520
What they claim to have backed
From their own portfolio page (on their website)
3 of 7 we have independently watched raise
CareSignalSono MotionVerax BiomedicalBrainbox SolutionsCoNextionsOptivioUID Identification Solutions
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed6 in all
Enanta PharmaceuticalsListed$56MMar 2013
Claros DiagnosticsBought by OPKO HealthUndisclosedOct 2011
Spirus MedicalBought by Olympus CorporationUndisclosedJul 2011
Phase ForwardBought by Oracle Corporation$685MApr 2010
Pintex PharmaceuticalsBought by VernalisUndisclosedApr 2005
Angiolink CorporationBought by MedtronicUndisclosedSept 2003
An exit counts when it came after the firm's first round in the company. From historical deal records.